{
    "nct_id": "NCT04937166",
    "official_title": "An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* White Blood Cell count < 20 x 10^9/L.\n* Adequate organ function\n* Relapsed/refractory AML or MDS/CMML patients who have failed up to 2 prior therapeutic regimens.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Acute Promyelocytic leukemia\n* Symptomatic central nervous system (CNS) leukemia or patients with poorly controlled CNS leukemia\n* Life-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy\n* Immune-mediated adverse reaction that required discontinuation of prior immunotherapy\n* Past or current history of autoimmune disease or immune deficiency\n* History of severe interstitial lung disease or severe pneumonitis or active pneumonitis\n* Clinically significant and poorly compensated liver disease\n* Prior organ allografts (such as renal transplant) requiring active immunosuppression\n* Active graft versus host disease\n* Treatment with systemic immunostimulatory within 4 weeks prior to initiation of study treatment\n* Treatment with any CD47/SIRPÎ± targeting agent or immune agonists\n* Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product\n* Received live, attenuated vaccine within 4 weeks prior to first dose of study treatment\n* Active Hepatitis B or C infection\n* History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease\n* Pregnant or breast feeding or planning to become pregnant while enrolled in the study",
    "miscellaneous_criteria": ""
}